Home Mainline IPOs Onyx Biotec Limited IPO
Orion Industries logo

Onyx Biotec Limited IPO

Open Sme
NSE 13 November - 18 November 2024
Onyx Biotec Limited IPO is a book build issue of 29.34 Cr. The issue is entirely a fresh issue of 4810000 shares aggregating to 29.34 Cr. Onyx Biotec Limited IPO opened for subscription on Nov 13, 2024 and closed on Nov 18, 2024. The allotment for the this IPO was finalized on Nov 19, 2024. IPO was listed on NSE and BSE on Nov 21, 2024. Onyx Biotec Limited IPO is set issue price band at ₹58 to ₹61 per share.

Current GMP

₹5 (+8.20%)

Price Band

₹ 58 – 61

Lot Size

2000

Issue Size

₹29.34 Cr

Minimum Investment

₹244000 (4000 Shares)

Listing Date

21 November 2024

Subscription

198.08x

About the Company

Onyx Biotec Limited, originally incorporated as Onyx Biotec Private Limited in 2005, was converted into a public limited company in 2024, adopting its current name. The company operates in the pharmaceutical industry, specializing in the manufacture and supply of sterile pharmaceutical products, including Sterile Water for Injections, Dry Powder Injections, and Dry Syrup. It also acts as a contract manufacturer for a range of pharmaceutical products for both domestic and international markets.

Core Business and Products:

  • Sterile Water for Injections: Onyx Biotec started operations in 2010 with this product and has grown to become a prominent supplier to major pharmaceutical companies in India.
  • Dry Powder Injections and Dry Syrups: The company manufactures these products for various pharmaceutical companies and healthcare providers in India and abroad.
  • Contract Manufacturing: Onyx provides end-to-end product development and manufacturing solutions, including regulatory filing support for both Indian and global markets.

Manufacturing Facilities: Onyx operates two manufacturing units in Himachal Pradesh:

  • Unit I: Located in Ropar, it has a capacity of producing 638,889 units of Sterile Water for Injections per day.
  • Unit II: Located in Nalagarh, it has a production capacity of 40,000 units of Dry Powder Injections and 26,667 units of Dry Syrup per day (in a single shift).

Both units are equipped with modern equipment, follow sustainable practices, and are accredited by global regulatory agencies, including WHO-GMP (Good Manufacturing Practices). These facilities undergo regular audits by clients and regulators to ensure adherence to quality standards.

Key Clients: Onyx has established long-term relationships with leading pharmaceutical companies, including:

  • Hetero Healthcare Limited
  • Mankind Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Aristo Pharmaceuticals Private Limited
  • Macleods Pharmaceuticals Limited
  • Axa Parenterals Limited
  • FDC Limited
  • Zuventus Healthcare Limited
  • Akums Drugs and Pharmaceuticals Limited
  • Reliance Life Sciences Limited

Onyx Biotec Limited is a growing player in the pharmaceutical manufacturing sector, known for its high-quality sterile products and strong client relationships. The company is focused on expanding its capabilities through strategic investments in manufacturing upgrades and packaging technology, aiming to strengthen its market position both in India and internationally. 

Promoters

  1. Sanjay Jain
  2. Naresh Kumar
  3. Fateh Pal Singh
Promoters Holding

Holding Pre Issue

88.60%

Holding Post Issue

0.00%

Objects of the Issue

The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:

  1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use.
  2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections.
  3. Prepayment or repayment of all or a portion of certain loans availed by the Company.
  4. General Corporate Purposes.

Address / Contact Info

Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road, District Solan –
174 101, Himachal Pradesh

 Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com

IPO Snapshot

Face Value₹10 per share
Price Band₹ 58 – 61
Lot Size2000
Issue TypeBook-building IPO
Sale Type
Fresh Issue₹ 29.34 Cr
Offer for Sale₹ 0.00 Cr
Total Issue Size₹ 29.34 Cr
Listing AtNSE
Industry
Sector
QIB Quota18.96%
Retail Quota33.26%

Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.

Frequently Asked Questions

Everything you need to know before applying to an IPO.

Onyx Biotec Limited IPO is a Book-building IPO worth ₹29.34 crores. The price band is ₹58 to 61 per share. The IPO opens on Wed, Nov 13, 2024 and closes on Mon, Nov 18, 2024. It will be listed on BSE and NSE. Mas Services Limited is the registrar.

The Onyx Biotec Limited IPO opens on Wed, Nov 13, 2024 and closes on Mon, Nov 18, 2024

Onyx Biotec Limited IPO Price Band is ₹58 to 61.

Onyx Biotec Limited IPO lot size is 2000, and the minimum amount required for application is ₹244000.

The minimum investment for Onyx Biotec Limited IPO is approximately ₹244000 based on the upper price band.

To apply for the Onyx Biotec Limited IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Mon, Nov 18, 2024. After submission, funds are blocked until the basis of allotment of Onyx Biotec Limited IPO is finalised.

Onyx Biotec Limited IPO issue size is ₹29.34 crores.

Onyx Biotec Limited IPO allotment date is Sat, Jun 27, 2026.

The registrar for Onyx Biotec Limited IPO is Mas Services Limited. Investors can go to Mas Services Limited website for IPO allotment status, refund processing, and other queries related to Onyx Biotec Limited IPO through their official website or helpline.

The Onyx Biotec Limited IPO GMP (Grey Market Premium) is ₹5 as of Fri, Nov 22, 2024. Based on the upper price band of ₹61 per share, the estimated Onyx Biotec Limited IPO listing price is ₹66, indicating a potential listing gain of approximately 31% over the issue price.